BONE MORPHOGENETIC PROTEIN MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2024 - 2031)

Bone Morphogenetic Protein Market, By Type (Recombinant Bone Morphogenetic Proteins (rhBMPs), Synthetic Bone Morphogenetic Proteins, and Natural Bone Morphogenetic Proteins), By Application (Orthopedic Surgeries, Dental Surgeries, Spinal Surgeries, Craniofacial Surgeries, and Other Applications), By End User (Hospitals, Ambulatory Surgical Centers, Research Institutions, and Others), By Geography (North America, Latin America, Asia Pacific, Europe, Middle East, and Africa)

In March 2024 CGBio, a South Korea-based biopharmaceutical company, received the U.S. FDA approval for its Novosis Putty solution, a moldable, bioactive bone graft material designed to enhance surgical outcomes. Novosis integrates recombinant human bone morphogenetic protein-2 (rhbone morphogenetic protein-2, Nebotermin) with ceramic scaffolds to promote bone growth during spinal and orthopedic surgeries.
In March 2024 Merck KGaA, a global science and technology company, transitioned its eCommerce operations in Indonesia to the global platform which is SigmaAldrich.com .This transition enables the company to offer customers better features such as pricing in Indonesian Rupiah (IDR), enhanced search capabilities, a comprehensive product portfolio, and real-time stock updates for a smoother shopping experience.
In August 2023, Qkine, a U.K.-based biotechnology company, announced a distribution partnership with Biogenuix in India to expand the availability of its animal-free, bioactive proteins for stem cell and organoid culture in the growing Indian market
In April 2023, Qkine launched a new biomanufacturing and R&D facility in Cambridge, U.K., to scale up the production of high-purity, animal-free proteins, catering to the rising global demand in stem cell research, cultivated meat, and regenerative medicine